Edwards’ Resilia Surgical Valve Proves Durability in COMMENCE Study
Four-year data from the COMMENCE trial of surgical valves made of Resilia bovine pericardial tissue showed no early or late structural valve deterioration or valve thrombosis.
You may also be interested in...
Edwards Beat Analysts' And Its Own Projections in Q2 As TAVR Volumes Recover
The company recorded $925m in revenue in the second quarter of 2020, exceeding the top end of its previous guidance, and expects to return to growth by the end of the year.
Edwards Invests In Mitral, Tricuspid Solutions As TAVR Growth Exceeds Expectations
Sales of Sapien transcatheter aortic valves grew about 27% year over year in the third quarter of 2019 while revenues from Edwards’ transcatheter mitral and tricuspid therapies grew to almost $10m, led by sales of the Pascal transcatheter mitral repair system in Europe.
Edwards Discontinues Centera TAVR Program As Sapien Sales Continue To Climb
Edwards Lifesciences is giving up on the Centera transcatheter aortic valve replacement (TAVR), despite promising clinical results, to focus on its Sapien TAVR line. The company reported overall revenue of $1.1bn in the second quarter of 2019, representing 14% year-over-year growth, driven by 18% growth in sales of Sapien systems.